CASI Pharmaceuticals, Inc. (CASIF)
↓ Download CSV- Sector Manufacturing
- Incorporated E9
- Fiscal year ends Dec 31
In fiscal 2025, CASI Pharmaceuticals, Inc. reported revenue of $20.71M, down 27.4% from the prior year. The company ran a net loss, with a net margin of -232.0% and a gross margin of 48.6%. It held $25.65M in total assets against $62.93M in total liabilities.
Key ratios (FY2025)
48.6%
Gross margin
-217.3%
Operating margin
-232.0%
Net margin
-27.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $20.71M | $28.54M | $33.88M | $43.11M | $30.17M | $15.14M | — |
| Cost of Revenue | $10.64M | $17.39M | $13.83M | $15.83M | $12.56M | $9.51M | — |
| Gross Profit | $10.08M | $11.15M | $20.05M | $27.28M | $17.61M | $5.63M | — |
| Operating Income | -$45.01M | -$39.62M | -$25.08M | -$34.03M | -$41.52M | -$52.78M | — |
| Net Income | -$48.06M | -$39.26M | -$26.96M | -$41.01M | -$36.65M | -$48.29M | — |
| EPS (Diluted) | $-2.59 | $-2.56 | $-2.02 | $-3.01 | $-2.69 | $-4.37 | — |
| Total Assets | $25.65M | $53.67M | $75.27M | $96.23M | $138.30M | — | — |
| Total Liabilities | $62.93M | $51.82M | $51.10M | $29.30M | $30.34M | — | — |
| Shareholders' Equity | -$37.28M | $1.85M | $24.16M | $44.57M | $84.50M | $81.54M | $73.00M |
| Cash & Equivalents | $5.63M | $13.47M | $17.08M | $47.11M | $38.70M | — | — |
| Operating Cash Flow | -$20.75M | -$29.22M | -$19.97M | -$21.09M | -$26.84M | -$25.89M | — |
| Capital Expenditures | $16.0K | $223.0K | $204.0K | $5.61M | $8.95M | $1.50M | — |
| Shares Outstanding | 18.54M | 15.34M | 13.36M | 13.65M | 13.61M | 11.05M | — |